breast cancer-specific mortality(English)

• changing trends are of great importance to physicians and patients with regards to treatment decisions and adjuvant treatment trial design. Furthermore, there is a close relationship between ER status and metastasis-specific survival. Patients with ER-negative/HER2-negative tumors had a median survival of 10 months after the detection of distant metastasis, and those with ER-negative/HER2-positive tumor survival of 19 months
• DCIS, ER, FBC, ITC, LABC, MM, PR, SEER, HER2
• Oncology, Woman /female, Decision making
• https://doi.org…al.pone.0157322